A nurse-led patient education program at Fox Chase Cancer Center in Philadelphia significantly improved how patients with kidney cancer understand clinical trials, particularly regarding the use of placebos and random assignment. Reported on October 26, 2026, according to Oncology Nursing News, the single-center study evaluated 101 kidney cancer patients who had never previously participated in a clinical trial. By pairing an in-person educational session with a short animated video during routine clinic visits, oncology nurses helped dispel common fears and misconceptions that frequently complicate treatment decisions.
Clinical trials are vital for advancing kidney cancer care, yet patient hesitation often stems from misunderstandings about how studies operate. To address these barriers, investigators first gathered insights from a focus group of 8 patients with kidney cancer, using semi-structured interviews to build targeted educational materials. When tested among the 101 trial-naïve participants, the program doubled the proportion of patients who understood that placebos are rarely used alone in kidney cancer studies, while reducing concerns about the time and financial commitments of trial participation.
Dispelling Common Misconceptions About Placebos and Randomization
One of the most frequent worries among oncology patients is the fear of receiving a sugar pill instead of active treatment. Nurse researcher Lambert noted in the report that placebo use comes up constantly during the consent process, calling it a question that almost every patient asks. In reality, modern oncology trials for kidney cancer rarely use a placebo by itself; patients typically receive at least the current standard of care, sometimes combined with either an investigational therapy or a placebo.
Before the educational intervention, only 29.0% of the surveyed patients correctly understood that a placebo is almost never used by itself in kidney cancer trials. Following the nurse-led session and animated video, correct understanding rose to 61.7% (P < .001).
The program also clarified the concept of randomization—the process of assigning patients to different study groups by chance rather than personal choice or physician preference. As research nurse Virag explained, many patients view randomization like flipping a coin without understanding the safeguards built into study designs. After completing the educational module, the percentage of patients who accurately recognized randomization as assignment by chance increased from 57.9% to 80.9% (P < .001).
Broader measures of patient confidence also improved. On a 1-to-5 scale, patients' average self-rated understanding of clinical trials rose from 3.27 before the session to 3.95 afterward (P < .001). Similarly, their confidence in knowing how to locate reliable clinical trial information increased from an average score of 3.24 to 3.88 (P < .001).
Addressing Financial Realities and Time Commitments
Beyond clinical design, practical worries about out-of-pocket expenses, insurance coverage, and scheduling often deter patients from exploring research options. On a 0-to-4 scale measuring worry about the cost and time required to participate in a study, the intervention helped lower average patient concern from 1.59 to 1.22 (P = .03).
However, the education also aimed to set realistic expectations regarding health insurance. Virag pointed out that some patients mistakenly assume that enrolling in a clinical study means every medical expense is automatically covered by the researchers. In practice, while a study sponsor typically covers the cost of the investigational drug and research-specific tests, routine care costs are still billed to the patient's insurance.
When the researchers measured specific concerns regarding insurance coverage before and after the session, the average score shifted from 1.29 to 1.09 on the 0-to-4 scale—a change that was not statistically significant (P = .11). Because clearing up coverage myths involves explaining that insurance is still required for routine care, better information may naturally temper unrealistic expectations while reassuring patients who feared total lack of coverage.
Fitting Education Into Busy Clinic Workflows
Delivering personalized education in a bustling oncology practice presents logistical challenges, particularly regarding examination room space and staff time. To avoid disrupting clinical care, the nursing team adapted their approach to fit around existing patient schedules.
According to study investigator Costello, nurses provided patients with study iPads and headphones so they could watch the animated educational video during natural downtime—such as while waiting for laboratory work, before seeing their physician, or even in the infusion chair while receiving treatment. Looking ahead, Lambert noted that the Fox Chase team is exploring ways to share the video with newly diagnosed kidney cancer patients directly through the hospital's online patient portal before their first provider appointment. That early access could help patients arrive ready to ask whether they are eligible for any clinical trials.
Importantly, the nurses emphasized that their goal is informed decision-making rather than persuading every patient to enroll. Costello stressed that the nursing role is to ensure patients fully understand what a trial entails so they can make an educated choice that aligns with their personal needs. For those who do enroll, Virag noted that nurse-led education remains an ongoing conversation from initial consent through the first day of therapy and beyond, as new questions naturally arise during treatment.
What This Means for Patients and Trial Enrollment
While the Fox Chase initiative succeeded in boosting patient knowledge and easing concerns about time and costs, improved understanding did not immediately translate into a higher stated desire to join a study. On a 5-point scale, patients' average willingness to consider a clinical trial was 3.44 before the education and 3.52 afterward, a difference that was not statistically significant (P = .33). The investigators suggested this finding may reflect a relatively high baseline openness to trials among the participants surveyed, alongside existing familiarity with concepts they did not view as obstacles.
Did the program increase actual clinical trial enrollment?
The study measured changes in patient knowledge, confidence, and perceptions during a single clinic visit, but it did not track whether participants eventually enrolled in a clinical trial. Determining whether nurse-led video education increases actual enrollment rates or maintains knowledge gains over time will require follow-up research across broader clinical settings.
How can patients use these findings at their own clinic?
Even if a hospital does not offer an animated educational program, patients with kidney cancer can ask to speak with an oncology research nurse early in their care. Asking direct questions—such as how standard treatments are used alongside study drugs, how randomization works for a specific protocol, and which costs are billed to insurance versus covered by the trial sponsor—can help patients evaluate all available treatment options with clarity and confidence.